<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="2374">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03075982</url>
  </required_header>
  <id_info>
    <org_study_id>43697715.0.0000.5053</org_study_id>
    <nct_id>NCT03075982</nct_id>
  </id_info>
  <brief_title>Respiratory Muscle Training in Hemodialysis Patients: Effects on Endothelium and Oxidative Stress Biomarkers</brief_title>
  <official_title>Respiratory Muscle Training in Hemodialysis Patients: Effects on Endothelium and Oxidative Stress Biomarkers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Universidade Federal do Ceara</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Universidade Federal do Ceara</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Hemodialysis patients have altered pulmonary function and this is associated with impaired
      endothelial function and cardiovascular events. Respiratory muscle training (RMT) has the
      potential to improve cardiovascular outcomes in patients undergoing maintenance HD.This is a
      randomized controlled clinical trial including 41 patients undergoing thrice-weekly
      maintenance HD. Patients were randomly assigned in a 2:1 ratio to receive or not RMT during
      HD sessions for 8 weeks. Main outcomes were change in levels of the biomarkers related to
      endothelium activation (vascular cell adhesion molecule 1, VCAM-1, and intercellular
      adhesion molecule 1, ICAM-1), glycocalyx derangement (syndecan-1), aberrant angiogenesis
      (angiopoietin-2) and oxidative stress (malondialdehyde) from baseline. Other outcomes
      included changes in functional capacity and in pulmonary function test
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">January 6, 2017</start_date>
  <completion_date type="Actual">March 24, 2017</completion_date>
  <primary_completion_date type="Actual">March 23, 2017</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>2:1 randomization</intervention_model_description>
    <primary_purpose>Prevention</primary_purpose>
    <masking>No masking</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Glycocalyx biomarker</measure>
    <time_frame>8 weeks</time_frame>
    <description>Plasma syndecan (ng/ml)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Endothelium biomarker</measure>
    <time_frame>8 weeks</time_frame>
    <description>Plasma VCAM(ng/mL)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>endothelium biomarker 2</measure>
    <time_frame>8 weeks</time_frame>
    <description>Plasma ICAM (ng/mL)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>aberrant angiogenesis</measure>
    <time_frame>8 weeks</time_frame>
    <description>Angiopoietin-2 (pg/mL)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Oxidative stress</measure>
    <time_frame>8 weeks</time_frame>
    <description>Plasma Malondialdehyde (mmol/L)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Blood Pressure</measure>
    <time_frame>8 WEEKS</time_frame>
    <description>Blood pressure (MMHG)</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">48</enrollment>
  <condition>Respiratory Muscle Training</condition>
  <arm_group>
    <arm_group_label>RespiratoryMuscle Training</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Group of patients submitted to respiratory muscle training with threshold for 8 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>No intervention</description>
  </arm_group>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Respiratory muscle training</intervention_name>
    <description>Respiratory muscle training with threshold</description>
    <arm_group_label>RespiratoryMuscle Training</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  patients receiving thrice-weekly maintenance HD for at least 3 months,

          -  cognitive and physical abilities to perform the study protocol procedures

        Exclusion Criteria:

          -  chronic pulmonary disease

          -  patients with acute coronary syndrome, decompensated heart failure, major infectious
             process or hospitalization within the last 3 months.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Alexandre Liborio, PHD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Universidade Federal do Ceara</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Pronefron</name>
      <address>
        <city>Fortaleza</city>
        <state>Ceara</state>
        <zip>60165082</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Brazil</country>
  </location_countries>
  <verification_date>March 2017</verification_date>
  <lastchanged_date>March 24, 2017</lastchanged_date>
  <firstreceived_date>March 6, 2017</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Universidade Federal do Ceara</investigator_affiliation>
    <investigator_full_name>Alexandre Braga Liborio</investigator_full_name>
    <investigator_title>Visitant Professor</investigator_title>
  </responsible_party>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
